MYTELASE® (ambenonium chloride)
MYTELASE, brand of ambenonium chloride, is [Oxalylbis (iminoethylene)] bis[(o -chlorobenzyl) diethylammonium] dichloride. The compound is a cholinesterase inhibitor with all the pharmacologic actions of acetylcholine, both the muscarinic and nicotinic types.
This drug is indicated for the treatment of myasthenia gravis.
Media Articles Related to Mytelase (Ambenonium)
Source: MedicineNet Genetic Disease Specialty [2015.03.12]
Title: Myasthenia Gravis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/12/2015 12:00:00 AM
Published Studies Related to Mytelase (Ambenonium)
Sensitive determination of ambenonium in plasma using inhibitory activity to acetylcholinesterase. [1993.03]
A sensitive analytical method for the determination of ambenonium, a selective acetylcholinesterase inhibitor, in plasma was developed. The procedure involves ultrafiltration to remove endogenous plasma cholinesterase, followed by colorimetric measurement of the inhibitory activity to acetylcholinesterase by the thiocholine method...
Influence of food on serum ambenonium concentration in patients with myasthenia gravis. 
Influence of food on the serum concentration and kinetics ambenonium chloride (AMBC) has been examined in thirteen patients with myasthenia gravis (MG). Mean serum concentrations and Cmax during fasting were higher than those in the non-fasting state...
Pharmacokinetics of ambenonium chloride in dogs after intravenous and oral administration. [1989.02]
Plasma concentrations of ambenonium chloride (Mytelase) were studied, using a high pressure liquid chromatographic technique, in 11 dogs, after intravenous or oral administration of the drug. The results found suggest a complex multi-compartment storage with several periodical releases in general circulation..
Page last updated: 2015-03-12